PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
226.57%
Net income growth above 1.5x CRK's 28.74%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-48.89%
Both reduce yoy D&A, with CRK at -42.26%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
1240.68%
Well above CRK's 31.28% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
98.30%
Well above CRK's 0.69% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while CRK is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-23.02%
Both negative yoy, with CRK at -92.80%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
21.05%
Some CFO growth while CRK is negative at -32.28%. John Neff would note a short-term liquidity lead over the competitor.
18.58%
CapEx growth well above CRK's 35.90%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-155.78%
Negative yoy acquisition while CRK stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
168.74%
Purchases growth of 168.74% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-162.53%
We reduce yoy sales while CRK is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-157.56%
We reduce yoy other investing while CRK is 200.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
365.10%
We have mild expansions while CRK is negative at -6.18%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
17.77%
Debt repayment growth of 17.77% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
227.31%
Lower share issuance yoy vs. CRK's 1606.23%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
-186831.83%
We cut yoy buybacks while CRK is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.